Table 2 Baseline laboratory data.

From: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel

Characteristics

 

Cohort 1 (n = 255)

Cohort 2 (n = 159)

White blood cell count, /μL

Median (range)

6050 (2400–23,650)

4750 (1620–21,910)

Neutrophil count, /μL

Median (range)

3940 (770–20,810)

2900 (610–21,250)

Lymphocyte count, /μL

Median (range)

1360 (230–8640)

1080 (190–3030)

Platelet count, × 104/μL

Median (range)

20.7 (6.7–56.1)

18.3 (2.4–79.8)

Albumin concentration, g/dL

Median (range)

3.8 (2.2–4.8)

3.6 (1.5–4.6)

CRP, mg/dL

Median (range)

0.33 (0.01–17.00)

0.58 (0.01–16.33)

LDH, U/L

Median (range)

180 (74–1320)

208 (84–713)

CEA, ng/mL

Median (range)

5.5 (0.4–626.6)

7.5 (1.0–1379.3)

CA19-9, U/mL

Median (range)

832 (1–6,554,100)

1254 (1–7,200,000)

NLR

Median (range)

3.02 (0.28–36.88)

2.68 (0.37–49.4)

 

≥ 5.00, n (%)

46 (18)

34 (21)

PLR

Median (range)

150.9 (16.1–1344.8)

164.5 (35.8–1270.0)

 

≥ 150.0, n (%)

128 (50)

89 (56)

PNI

Median (range)

45 (25–66)

42 (19–54)

 

< 47, n (%)

157 (62)

133 (84)

CAR

Median (range)

0.084 (0.002–7.182)

0.157 (0.003–6.387)

 

≥ 0.540, n (%)

62 (24)

40 (25)

GPS, n (%)

0

146 (57)

80 (50)

 

1

62 (24)

48 (30)

 

2

47 (18)

31 (20)

PI, n (%)

0

165 (65)

100 (63)

 

1

82 (32)

49 (31)

 

2

8 (3)

10 (6)

  1. CRP C-reactive protein, LDH lactate dehydrogenase, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19–9, NLR neutrophil-to-lymphocyte ratio, PLR platelet-lymphocyte ratio, PNI prognostic nutrition index, CAR CRP-albumin ratio, GPS Glasgow prognostic score, PI prognostic index.
Back to article page